Neuroscience Parkinson's

Parkinson’s drug to Treat OFF Episodes Hits Right Notes in Phase 3 Study

Sunovion Pharmaceuticals Inc. announced top line results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trials from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes). Study CTH-300 met its primary and key secondary endpoints, […]